CRISPR Therapeutics’ IPO Falls Short Of Target

October 19, 2016 | The gene-editing technology company with Cambridge operations sold 4 million share at $14 each. It had planned to sell 4.7 million shares at $15 to $17 apiece. The Boston Globe